S. Nihira

Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.

M. Fukuoka, N. Masuda, N. Yamamoto, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Development of HER2-specific humanized antibody Herceptin (trastuzumab).

S. Nihira, 2003, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Induction of class II major histocompatibility complex blockade as well as T cell tolerance by peptides administered in soluble form

F. Falcioni, Z. Nagy, D. Bolin, 1996, European journal of immunology.

Thymosin α1 enhances haemopoietic colony formation by stimulating the production of interleukin 3 in nu/nu mice

Y. Yagi, Y. Ohta, S. Nihira, 1986 .

Anti-angiogenic therapy against gastrointestinal tract cancers.

J. Iwasaki, S. Nihira, 2009, Japanese journal of clinical oncology.

Guidelines for clinical evaluation of anti‐cancer drugs

Toshio Shimizu, K. Nishio, A. Ohtsu, 2021, Cancer science.

A new hematopoietic cell line, KMT-2, having human interleukin-3 receptors.

T. Suda, C. Miyamoto, M. Sugawara, 1990, Blood.

Familial mental retardation associated with balanced chromosome rearrangement rcp t(8;11)(q24.3;p15.1).

H. Fujita, S. Nihira, H. Sato, 1989, Journal of medical genetics.

Analysis of proteases involved in phagocytic activity of macrophages through the use of various amino acid esters.

S. Nihira, J. Koyama, 1983, Journal of biochemistry.

Screening of an inhibitor of the tetracycline efflux pump in a tetracycline-resistant clinical-isolate of Staphylococcus aureus 743.

A. Yamaguchi, J. Nielsen, T. Satoh, 1998, Biological and Pharmaceutical Bulletin.